Etfs S&p Biotech ETF (ASX: CURE) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Etfs S&p Biotech ETF Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Etfs S&p Biotech ETF (ASX: CURE)
Latest News
ETFs
2 top ETFs for ASX investors to buy in October
ETFs
2 exciting ETFs named as buys by experts
CURE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Oliver Joseph Reynolds | Non-Executive Director | Sep 2023 |
Mr Reynolds has over 20 years of experience in financial services and investment management, with experience leading finance, operations, risk management, compliance, investment, strategy and management teams. Oliver previously worked at BlackRock, and most recently at Coolabah Capital as Chief Financial Officer.
|
| Mr Evan Metcalf | Non-Executive Director | Jun 2022 |
Mr Metcalf has more than 20 years of experience in financial services which includes derivative structuring roles at Credit Suisse and ANZ, as well as a role as a quantitative analyst at Westpac
|
| Young Kim | Non-Executive Director | Jun 2022 |
No Profile Reported in Annual Report.
|
| Mr Namki Kim | Non-Executive Director | Jul 2024 |
--
|
| Mr Emanual Damianakis | Non-Executive Director | Aug 2024 |
--
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| No Top 20 Shareholder Information | 0 | 0.00% |
